| Revenue growth | 19.1% YoY |
|---|---|
| Margins | EBITDA margin improved to 31% from 28.7% YoY. |
| Demand visibility | Strong, driven by lifestyle diseases and health awareness. |
| Management confidence | High, citing resilient growth trajectory and operational momentum. |
Growth
Revenue rose 19.1% to Rs. 798 Cr; EBITDA up 28.7% to Rs. 247 Cr; PAT grew 27.2% to Rs. 170 Cr.
Outlook
Focusing on high-complexity portfolios and AI-powered diagnostics. Expanding reach into rural markets via GraminFit program.
Risks
Fragmented industry competition; structural shifts toward regular preventive testing require constant investment in digital infrastructure.
Last quarter's promises, checked
Delivered
- Guided early to mid-teens revenue growth → delivered 19.1% (= BEAT)
- Guided 27%-28% EBITDA margin → delivered 31.0% (= BEAT)
- Guided sustaining patient volume growth → delivered 8.2% (= BEAT)
Partly delivered
- Guided Rs. 100-120 Cr annual capex → Q1 cash position increased to Rs. 1,693 Cr (= PARTIAL)
Investor Presentation filed with BSE, NSE: LALPATHLAB. Summary written with AI assistance from the document.
Dr. Lal Pathlabs Ltd: key numbers
- Share price
- ₹1,952.30
- Market cap
- ₹32,769 Cr
- Revenue (annual)
- ₹2,763 Cr
- Net profit (annual)
- ₹504.8 Cr
- P/E (TTM)
- 60.5×Sector 57.8×
- Promoter holding
- 53.19%-0.02% QoQ
- FII holding
- 17.35%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Dr. Lal Pathlabs Ltd
All →Dr. Lal Pathlabs Acquisition Worth ₹38 Cr
Dr. Lal Path Labs' subsidiary completed the acquisition of an 80% stake in Sunshine Healthcare Limited, Ghana, for Rs.38.00 Crore. The target is now a subsidiary.
- Value
- ₹38.00 Cr
Dr. Lal Pathlabs Acquisition
Dr. Lal PathLabs' subsidiary, DLPL Dubai, completed the acquisition of an 80% stake in Sunshine Healthcare Limited, Ghana. Sunshine Healthcare is now a step-down subsidiary.
Dr. Lal Pathlabs Board Meeting Date
Dr. Lal PathLabs will hold a board meeting on November 04, 2026, to consider and approve standalone and consolidated financial results for the quarter ending September 30, 2026.
Dr. Lal Pathlabs Employee Stock Options
Designated persons and the company's Employee Welfare Trust disclosed multiple equity transactions, including ESOP exercises and market sales, in a recent regulatory filing.
- Value
- ₹1.42 Cr
Dr. Lal Pathlabs Acquisition Worth ₹168 Cr
Dr. Lal Path Labs Ltd. will acquire a 70% stake in SN Genelab Private Limited for Rs. 168 Crore to strengthen its genomics diagnostics portfolio.
- Value
- ₹168.0 Cr
Dr. Lal Pathlabs Acquisition Worth ₹199.5 Cr
Dr. Lal PathLabs approved the acquisition of a 70% stake in SN Genelab Private Limited for a total consideration of up to ₹199.5 Crore.
- Value
- ₹199.5 Cr